Objective: To determine the humoral immune response after a four-site intradermal (4-site ID) rabies booster vaccination in HIV-infected adults. Methods: We conducted a randomized, controlled trial to compare the Rabies Neutralizing Antibody (RNab) after a single visit 4-site ID boosters with 0.1 mL of purified Vero cell rabies vaccine (PVRV) per injection site distributed at both deltoids and anterior thighs vs. conventional intramuscular injections using a full ampule (0.5 mL) of PVRV at the deltoid on day 0 and 3 in thirty-eight previously rabies immunized HIV-infected participants whose CD4+ count ≥ 200 cell/mm3. Serum samples were taken prior to immunization, on day 7 and 14 for serological analysis of RNab by the Rapid Fluorescent Focus Inhibition Test (RFFIT). Results: The 4-site ID regimen could elicit higher RNab titers than IM, but without statistically significant. The geometric mean (95% confidence interval) of RNab in 4-site ID vs. IM group were 14.9 (10.2-37.9) vs. 12.9 (8.5-33.9) IU/mL on day 7 (p = 0.67) and 31.3 (23.9-65.7) vs. 19.8 (15.6-49.5) IU/mL on day 14 (p = 0.18) respectively. Conclusion: There were no significant differences in the immunogenicity of 4-site ID vs. IM rabies booster vaccination in individuals infected with human immunodeficiency virus.